Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
Study sponsor: NovoCure Ltd. · NVCR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-18Actual
Enrollment · participants540Actual
Source updated2024-03-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.